The planned number of subjects is 352. Subjects will be enrolled at up to 40 sites in the United States, Israel, and Europe (Austria, Italy, Portugal, France, Germany). Study duration is expected to be up to approximately 3 years. Subjects will be followed for a period of 12 months in order to effectively evaluate changes to the disease state. The expected duration of each subject's participation is approximately 13 months.